Female Hair Restoration Therapy: Options, Evidence and Candidacy

How female hair restoration differs from male pattern loss

Hair loss in women follows patterns that differ substantially from those seen in men, and these differences shape every aspect of evaluation and candidacy. Ludwig (1977) described the classification that still guides physicians today: women typically experience diffuse thinning over the crown while preserving the frontal hairline, a pattern categorized in three grades of severity. Male pattern loss, by contrast, follows a predictable recession of the frontal hairline and vertex balding.

Olsen and colleagues (2005) documented a second presentation in women — the 'frontal accentuation' or Christmas-tree pattern — in which thinning begins at the frontal scalp and widens posteriorly, but the distinction from Ludwig's description remains one of degree rather than mechanism. Both patterns reflect miniaturization of follicles in response to androgens, yet the distribution is usually more diffuse in women. This diffuse involvement carries significant implications for surgical candidacy: a woman whose donor zone at the back and sides of the scalp is also thinning lacks the stable reservoir of follicles required for transplantation.

The American Academy of Dermatology notes that thinning hair and hair loss in women may represent female pattern hair loss, but a dermatologist's examination is necessary because other conditions — including thyroid disease, iron deficiency, and autoimmune processes — can produce similar clinical pictures. The overlap means that women presenting with hair loss require a broader work-up than men, and the path to female hair restoration often begins with ruling out reversible causes.

The evaluation: history, scalp exam and labs where indicated

A thorough history captures the onset, duration, and progression of hair loss, as well as recent hormonal transitions such as pregnancy, postpartum recovery, or perimenopause. The physician examines the scalp under magnification to assess hair density, caliber variation, and miniaturization, and to identify any inflammation or scarring that would suggest a different diagnosis. The pattern of loss — whether diffuse, patterned, or localized to areas of tension — guides the differential.

Laboratory testing is ordered where the history or examination suggests a systemic cause. Olsen and colleagues (2005) outlined a work-up that may include serum ferritin to assess iron stores, thyroid-stimulating hormone, and in some cases androgens or vitamin D. A ferritin below 40 ng/mL, for instance, may contribute to shedding even in the absence of anemia, and correction can support recovery. The decision to test is individualized; not every woman with hair loss requires a full panel.

The exam also documents areas of preserved density. In female hair restoration, the stability of the donor zone is not assumed — it must be confirmed. A woman whose occipital and parietal scalp shows the same degree of miniaturization as the crown is not a candidate for follicular extraction, because the grafts harvested from a thinning donor will not persist.

Medication options and what the trials show

Topical minoxidil remains the most studied medication for hair loss in women. Lucky and colleagues (2004) published a 48-week randomized placebo-controlled trial in which both 5% and 2% topical minoxidil formulations produced significantly greater hair counts than placebo in women with female pattern hair loss. The response was dose-dependent, with the 5% formulation outperforming 2%. Individual responses vary, and the medication must be continued to maintain any benefit; discontinuation results in shedding of the newly supported follicles over several months.

Vañó-Galván and colleagues (2021) reported on a multicenter series of 1,404 patients using low-dose oral minoxidil off-label for hair loss. Hypertrichosis — unwanted hair growth elsewhere on the body — was the most common adverse effect, though discontinuation for side effects was uncommon. Oral minoxidil is prescribed by some physicians when topical application is not tolerated or practical, but it is used off-label for this indication and requires physician supervision.

Finasteride, which Kaufman and colleagues (1998) studied in men with favorable results, has not shown consistent efficacy in postmenopausal women and carries contraindications in women of childbearing potential. Anti-androgen medications such as spironolactone are prescribed off-label by some physicians for female pattern hair loss, but their use requires ongoing monitoring and discussion of risks and benefits. The American Academy of Dermatology emphasizes that thinning hair may improve with appropriate care, but the goal is typically fuller hair rather than a return to a full density.

PRP for women: a mixed literature

Platelet-rich plasma injections involve drawing a patient's blood, centrifuging it to concentrate platelets, and injecting the preparation into the scalp. The rationale is that growth factors released by platelets may support follicular activity. Gentile and colleagues (2015) published a randomized placebo-controlled half-head trial in men with androgenetic alopecia, finding increased hair density on the side that received PRP versus the placebo side. Other small trials, however, have not replicated this finding.

Puig and colleagues (2016) conducted a double-blind placebo-controlled pilot specifically in women with female pattern hair loss and did NOT show a significant objective difference between the PRP and placebo groups. Mapar and colleagues (2016) similarly found no significant benefit in a small randomized trial in men. Meta-analyses by Giordano and colleagues (2017) and Zhang and colleagues (2023) pooled available trials and reported increased hair density with PRP, but both noted substantial heterogeneity in preparation methods, injection protocols, and follow-up intervals.

de Oliveira and colleagues (2023) conducted a systematic review of PRP specifically in women and concluded that the evidence remains limited and heterogeneous. The lack of standardization across studies — differences in centrifugation speed, platelet concentration, activation method, and number of sessions — makes it difficult to draw firm conclusions. Some patients report subjective improvement; others see no change. PRP is offered at many practices, but individuals considering it should understand that the literature in women is not definitive.

Exosome scalp protocols: investigational, not FDA approved to treat any disease

Exosomes are small vesicles secreted by cells that carry proteins, lipids, and genetic material. The hypothesis is that exosomes derived from stem cells or other sources might deliver signaling molecules that support follicular function. Kost and colleagues (2022) reviewed the literature and noted that exosome evidence for hair regeneration is mostly preclinical — cell culture and animal models — with very few human studies. Gupta and colleagues (2023) conducted a systematic review of exosome use in hair restoration and found preliminary human evidence from small, non-standardized studies; product characterization and dosing vary, and safety data are limited.

Malih and colleagues (2026) published a systematic review of PRECLINICAL exosome studies in androgenetic alopecia, reinforcing that most of the data remain at the bench rather than the bedside. Balwi and colleagues (2026) reviewed adjunctive regenerative therapies around hair transplantation — including PRP, exosomes, and others — and described the evidence base as early and heterogeneous. Shin and colleagues (2017) reviewed small clinical trials of adipose-derived stem cell conditioned media in pattern hair loss, again noting limited sample sizes and variability.

The FDA's December 2019 Public Safety Notification on Exosome Products states that there are no FDA-approved exosome products and that the agency received reports of serious adverse events in patients in Nebraska who received unapproved exosome products. The FDA's Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes warns that such products are not FDA approved to treat any disease other than within approved clinical trials. Exosome scalp protocols are investigational. Individual responses vary, the literature is preliminary, and patients considering such protocols should discuss the current state of the evidence and the regulatory status with their physician.

When FUE is an option for a woman — and when it is not

The ISHRS 2025 Practice Census, a survey of member activity in 2024, found that follicular unit extraction was used in 68.2% of female surgical procedures, compared to 30.0% using strip or linear harvesting. Women represented 15.3% of all surgical patients, and scalp was the recipient area in 78.9% of female procedures. For non-surgical hair-restoration procedures, the split was 61.7% men and 38.3% women. The average FUE case involved 2,262 grafts, and over half of surgical patients were aged 30 to 49.

The single most important factor in candidacy for a woman is donor stability. FUE harvests individual follicular units from the back and sides of the scalp, and those grafts must come from a zone that is not itself undergoing miniaturization. A woman with Ludwig grade III diffuse thinning that extends throughout the donor area lacks the stable reservoir required for surgery. By contrast, a woman with a localized area of loss — a receded hairline, thinned temples, or a specific region of the crown — and a preserved donor zone may be an excellent candidate.

Eyebrow restoration is the most common non-scalp area in women, accounting for 12.2% of female procedures in the census. Hairline lowering and temple restoration are also frequent indications. The No-Shave Micrograft FUE technique, in which donor hair is left at length rather than clipped, is particularly relevant for women who wear their hair long and do not wish for a visibly shaved area during the recovery period. Dr. Charles Pereyra, MD, personally performs the Micrograft FUE procedure — both extraction and placement — and evaluates each patient's donor zone and recipient needs individually.

A woman whose scalp exam reveals diffuse thinning without a clear pattern, whose donor density is reduced, or whose hair loss is progressing rapidly is typically not a surgical candidate. The consultation exists to make that determination honestly, and to outline the alternatives — medication, PRP, investigational protocols — where surgery is not appropriate.

Traction, styling and scarring patterns the exam must rule out

Billero and Miteva (2018) describe traction alopecia as hair loss caused by tension from tight hairstyles such as braids, ponytails, extensions, or weaves. The pattern of loss follows the areas under greatest tension — the frontal hairline, temples, and the margins where hair is pulled. Early-stage traction alopecia may be reversible if the styling practice is discontinued, but late-stage cases develop scarring and irreversible follicle loss.

The distinction between traction alopecia and female pattern hair loss matters for candidacy and prognosis. A woman with early traction changes may recover density by changing her styling routine, whereas one with scarring may be a candidate for FUE to the affected hairline or temples. The scalp exam identifies erythema, follicular inflammation, or scarring that signals a different process. Other scarring alopecias — lichen planopilaris, frontal fibrosing alopecia, central centrifugal cicatricial alopecia — require biopsy and medical management before any surgical option is considered.

The history elicits styling practices, chemical relaxers, heat tools, and extensions. A woman who has worn tight braids for years and now presents with temple recession has a different etiology than one with diffuse crown thinning and no history of tension styling. Both may seek female hair restoration, but the evaluation and candidacy diverge.

How the Female Hair Restoration consultation at Springs works

The Female Hair Restoration consultation begins with a detailed history and a Follicular Health Assessment performed by Dr. Charles Pereyra, MD. The assessment includes scalp examination under magnification, documentation of hair density and caliber, and discussion of any hormonal, nutritional, or medical factors that may contribute. Where the history or exam suggests a systemic cause, Dr. Pereyra may recommend laboratory testing or referral to a dermatologist or endocrinologist before proceeding.

For women who are candidates for Micrograft FUE — those with a stable donor zone and localized areas of loss or specific cosmetic goals such as hairline refinement or eyebrow restoration — Dr. Pereyra personally performs both the extraction and placement phases. The procedure is not delegated to a physician assistant or technician. The goal, as the American Academy of Dermatology frames it, is fuller hair rather than a full density, and realistic expectations are established during the consultation.

Springs quotes one all-in price at the consultation. That price is individualized based on the number of grafts needed and the complexity of the case. For women who are not surgical candidates — because of diffuse donor thinning, active inflammation, or another contraindication — the consultation outlines alternative approaches: medication, PRP, investigational exosome scalp protocols, or continued observation with follow-up. The consultation is an evaluation, not a sales process.

Springs Rejuvenation operates five clinics: Aventura (Miami), Los Angeles, Austin, Atlanta, and New York. The phone number for every location is (888) 503-4482. For out-of-state patients, the travel program begins with a virtual consultation to review photos and history, followed by a written care plan. The patient then travels to the clinic for the procedure and an in-person recovery check before flying home. Remote follow-up continues thereafter. Springs has performed over 7,000 procedures and maintains more than 350 Google reviews.

Frequently asked questions

Can a woman have FUE without shaving her donor area?

No-Shave Micrograft FUE is designed for patients who prefer to keep their hair at length during the procedure and recovery. Individual follicular units are harvested without clipping the surrounding donor hair, allowing a woman to wear her hair down immediately afterward. The technique is particularly relevant for women with long hair who do not wish for a visibly shaved area. Not all cases are candidates for No-Shave FUE; the decision depends on graft number, donor density, and the patient's styling preferences, and is discussed during the consultation.

Does minoxidil work for women?

Lucky and colleagues (2004) published a randomized placebo-controlled trial showing that both 5% and 2% topical minoxidil produced significantly greater hair counts than placebo in women with female pattern hair loss at 48 weeks. The response is dose-dependent and individual responses vary. Minoxidil must be continued to maintain benefit; stopping the medication leads to shedding of newly supported follicles over several months. Some women experience scalp irritation. Oral minoxidil is used off-label by some physicians, with hypertrichosis the most common adverse effect (Vañó-Galván 2021).

Is PRP effective for female hair loss?

The evidence for platelet-rich plasma in women is limited and mixed. Puig and colleagues (2016) conducted a double-blind placebo-controlled pilot in women with female pattern hair loss and did NOT show a significant objective difference between PRP and placebo. de Oliveira and colleagues (2023) reviewed the literature specifically in women and concluded that studies remain heterogeneous in preparation methods and outcomes. Meta-analyses pooling trials across both sexes report increased hair density, but variability in protocols makes firm conclusions difficult. Some patients report subjective improvement; others do not.

Are exosome scalp therapies approved?

No. The FDA's December 2019 Public Safety Notification states that there are no FDA-approved exosome products, and the FDA received reports of serious adverse events in patients who received unapproved exosome products. The FDA's Consumer Alert warns that such products are not FDA approved to treat any disease other than within approved clinical trials. Gupta and colleagues (2023) and Kost and colleagues (2022) reviewed the literature and found that human evidence is preliminary, from small non-standardized studies, and that product characterization and safety data are limited. Exosome scalp protocols are investigational.

What labs might be ordered during a hair-loss evaluation?

Laboratory testing is individualized based on history and examination findings. Olsen and colleagues (2005) outlined a work-up that may include serum ferritin to assess iron stores, thyroid-stimulating hormone, and in some cases androgens or vitamin D. A low ferritin, even without anemia, can contribute to shedding and may be correctable. Thyroid dysfunction and hormonal imbalances are reversible causes of hair loss that warrant identification. Not every woman requires a full panel; the decision to test is guided by clinical suspicion and the pattern of loss observed on exam.

About the author: Dr. Charles Pereyra, MD, is a board-certified emergency physician (NewYork-Presbyterian Brooklyn Methodist), a member of the International Society of Hair Restoration Surgery (ISHRS), and the physician who personally performs Micrograft FUE procedures at Springs Rejuvenation Hair.

Medical disclaimer: Stem cell and exosome therapy is not an FDA approved therapy and is considered to be in the experimental stages; it is not FDA approved to treat any disease. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Reviewed for medical accuracy by Dr. Charles Pereyra, MD, Medical Director, Springs Rejuvenation.